A Phase II Study of Tepotinib in Patients with Stage IIIB-IV Lung Adenocarcinoma


Full Title

A Phase II single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)


Tepotinib is an investigational drug that can shrink tumors that have an altered version of the MET protein. In this study, researchers are evaluating the safety and effectiveness of tepotinib is patients with stage IIIB-IV lung adenocarcinomas that contain altered MET and which continued to grow despite at least one regimen of chemotherapy. Tepotinib is a tablet that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IIIB-IV lung adenocarcinoma that has continued to grow despite one but no more than two prior regimens of chemotherapy, at least one of which contained a platinum drug.
  • Patients’ tumors must contain a MET exon 14 splice site mutation.
  • At least 3 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study or to inquire about eligibility, please contact Dr. Paul K. Paik at 646-888-4202.